


CLINICAL TRIAL

Illuminate - NCT03913143

Retinal RED



A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber's Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate)

Rare Eye Disease concerned by the trial :
Leber's congenital amaurosis

Status of the trial : recruiting
Orphan drug recognition : No

Inclusion criteria : [Click here to see detailed criteria](#)

Exclusion criteria : [Click here to see detailed criteria](#)



Inclusion opening date : /2019



Inclusion closing date (previsional) : /2020

Children



Adults



Within ERN-EYE members



Locations of the trial :

CHNO des XV XX - Centre Hospitalier National d'Ophthalmologie
Paris, France

CARGO
Hôpitaux Universitaires de Strasbourg, France


Universitair Ziekenhuis Gent
Gent, Belgium

Universitätsklinikum Tübingen
Tübingen, Germany

Justus-Liebig Universität - Department of Ophthalmology
Gießen, Germany

Radboud University Medical Center,
Nijmegen, Netherlands

Moorfields Eye Hospital
London, United Kingdom, EC1V 2PD



Funder type : Industry

[More informations](#)